Medical News Today -- Boehringer Ingelheim welcomed the National Institute for Health and Clinical Excellence (NICE)'s Final Appraisal Determination (FAD) which gives a draft recommendation that Pradaxa® (dabigatran etexilate), within its marketing authorisation, is recommended as an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or elective total knee replacement surgery.1 Pradaxa® is the first oral anticoagulant for preventing venous thromboembolism (VTE) to be licensed in the UK for more than 50 years.
